Diagnosis

  • Colposcopy explained: What happens and what to expect

    Article produced in association with Spital Clinic Each year in England, approximately three million women take part in cervical screening. While the majority receive a reassuring result, a proportion are referred for further investigation following an abnormal finding or a positive human papillomavirus (HPV) test. For these women, the next step is a colposcopy. Despite [...]

  • Gene finding paves way for new targeted breast cancer treatment

    A gene linked to triple negative breast cancer could point to a new targeted treatment, researchers say. Triple negative breast cancer makes up about 15 per cent of breast cancer cases. This form of the disease can be more aggressive and harder to treat than other types, with fewer targeted treatment options available. It is [...]

  • Heart disease risk found in mammograms

    AI could help routine mammograms spot heart disease risk in women, as well as breast cancer, researchers have found. A team from Emory University analysed regular screening scans from more than 123,000 women who had no prior history of cardiovascular disease. Using an AI programme to quantify calcification and hardening in the arteries, they found [...]

  • Blood test shows promise in endometriosis

    A blood test for endometriosis showed clinical promise after detecting cases missed by standard imaging, according to a clinical validation study. HerAnova Lifesciences has published a peer-reviewed clinical validation study of its HerResolve blood test for endometriosis in the Journal of Minimally Invasive Gynecology, the official journal of the AAGL. The multi-centre study enrolled 298 [...]

  • Study reveals hidden menopause tech privacy concerns

    New research has revealed privacy and advice concerns surrounding tech aimed at helping women navigate the menopause. The study, which surveyed 310 UK participants, warns that sensitive data collected from women about their health is often vulnerable to exploitation, ranging from targeted financial scams to workplace discrimination and misinformation. With nearly one million women in [...]

  • Home urine tests could detect breast cancer, endometriosis and PCOS

    "Game-changing" home urine tests to detect early stage breast cancer are being developed in Wales, alongside similar work on endometriosis and polycystic ovary syndrome. Researchers said they hope to have a prototype kit within the next year to detect early stage breast cancer using a lateral flow urine sample. Lateral flow tests are simple strip-based [...]

  • Women in Scotland waiting more than 10 years for endometriosis diagnosis

    Women in Scotland wait more than 10 years on average for an endometriosis diagnosis, according to a survey conducted by Endometriosis UK. The charity, which raises awareness and aims to improve the lives of women with the condition, said the average diagnosis time is now 10 years and two months. That is an increase from [...]

  • Digital tools could cut endometriosis diagnosis delays

    Digital symptom checkers could reduce endometriosis diagnosis delays by more than four years and save over US$5,000 per patient, according to a modelling study. Endometriosis is a condition where tissue similar to the womb lining grows outside the uterus, often causing pelvic pain and other symptoms. In the US it takes about seven years on [...]

  • 60% of US women to have cardiovascular disease by 2050 – study

    Nearly six in 10 US women are projected to have cardiovascular disease by 2050, driven largely by rising rates of high blood pressure, according to a new American Heart Association scientific statement. Cardiovascular disease refers to conditions affecting the heart and blood vessels, including heart disease, heart failure, atrial fibrillation, which is an irregular heartbeat, [...]

  • FDA fast tracks BRCA breast cancer drug

    The US Food and Drug Administration (FDA) has granted fast track status to a new drug combination for BRCA-mutated advanced breast cancer. The designation covers ART6043, developed by Artios, used with the PARP inhibitor Lynparza, also known as olaparib. It applies to adults with germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer who have [...]